Skip to content

13F-HR filed by Stonepine Capital Management, LLC

Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2022-03-31, filed 2022-05-16, with 28 holding rows worth $241,108,000.

Accession
0001567619-22-010659
Filed
2022-05-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2022

A holdings report, 28 entries on the cover page, a total value of $241,108,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $241,108,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AMRYT PHARMA LTD - SPNR ADR03217L106COMMON EQUITY6,338,200$52,417,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM4,684,404$21,876,000thousands by filing date
XERIS BIOPHARMA HOLDINGS INC98422E103COM7,924,056$20,286,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW4,912,714$16,163,000thousands by filing date
OVID THERAPEUTICS INC690469101COMMON STOCK4,218,069$13,245,000thousands by filing date
ADMA BIOLOGICS INC000899104COM7,131,808$13,051,000thousands by filing date
ANTARES PHARMA INC036642106COM3,130,192$12,834,000thousands by filing date
CONFORMIS INC20717E101COM17,281,386$10,780,000thousands by filing date
APOLLO ENDOSURGERY INC03767D108COM1,693,834$10,248,000thousands by filing date
EXAGEN INC30068X103COM1,121,040$9,002,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM119,972$8,540,000thousands by filing date
LIGAND PHARMACEUTICALS INC53220K504COM NEW73,700$8,291,000thousands by filing date
OPTINOSE INC68404V100COM2,926,416$7,228,000thousands by filing date
QUIDEL CORP74838J101COM61,791$6,949,000thousands by filing date
EVOLUS INC30052C107COM586,224$6,577,000thousands by filing date
ATYR PHARMA INC002120202COM NEW601,580$3,218,000thousands by filing date
DIAMEDICA THERAPEUTICS INC25253X207COMMON STOCK1,197,245$2,993,000thousands by filing date
SYNLOGIC INC87166L100COM1,064,135$2,554,000thousands by filing date
REZOLUTE INC76200L309COMMON STOCK748,702$2,531,000thousands by filing date
UROGEN PHARMA LTDM96088105COMMON STOCK268,833$2,342,000thousands by filing date
SURGALIGN HOLDINGS INC86882C105COM7,375,678$2,244,000thousands by filing date
CELCUITY INC15102K100COM239,433$2,239,000thousands by filing date
CIDARA THERAPEUTICS INC COM NEW171757107Stock2,496,520$2,079,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK36,803$1,030,000thousands by filing date
AERIE PHARMACEUTICALS INC00771V108COM93,900$854,000thousands by filing date
ANI PHARMACEUTICALS INC00182C103COM26,060$733,000thousands by filing date
MARINUS PHARMACEUTICALS INC56854Q200COM NEW56,747$531,000thousands by filing date
NEUROONE MED TECHNOLOGIES CORP COM64130M209Stock248,105$273,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-22-010659this filing2022-05-16acceptance time not in the bulk data set